Olga M Klibanov

Summary

Affiliation: Wingate University
Country: USA

Publications

  1. ncbi request reprint IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection
    Olga M Klibanov
    Wingate University School of Pharmacy, Campus Box 3087, Wingate, NC 28174 0159, USA
    Curr Opin Investig Drugs 11:237-45. 2010
  2. doi request reprint Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C
    Olga M Klibanov
    School of Pharmacy, Wingate University, Wingate, North Carolina 28174, USA
    Pharmacotherapy 32:173-90. 2012
  3. ncbi request reprint Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection
    Olga M Klibanov
    Wingate University School of Pharmacy, Wingate, NC 28174 0159, USA
    Curr Opin Investig Drugs 10:190-200. 2009
  4. ncbi request reprint Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection
    Olga M Klibanov
    Wingate University School of Pharmacy, Wingate, NC 28174 0159, USA
    Curr Opin Investig Drugs 10:845-59. 2009
  5. ncbi request reprint Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection
    Olga M Klibanov
    Wingate University School of Pharmacy, Campus Box 3087, Wingate, NC 28174 0159, USA
    Curr Opin Investig Drugs 11:940-50. 2010
  6. doi request reprint Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C
    Olga M Klibanov
    School of Pharmacy, Wingate University, Wingate, North Carolina, 28174, USA
    Pharmacotherapy 31:951-74. 2011
  7. doi request reprint Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment
    Jacqueline L Olin
    School of Pharmacy, Wingate University, Wingate, NC, USA
    Ann Pharmacother 46:1671-7. 2012
  8. ncbi request reprint Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection
    Todd Correll
    Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA
    Pharmacotherapy 28:90-101. 2008

Collaborators

Detail Information

Publications8

  1. ncbi request reprint IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection
    Olga M Klibanov
    Wingate University School of Pharmacy, Campus Box 3087, Wingate, NC 28174 0159, USA
    Curr Opin Investig Drugs 11:237-45. 2010
    ..In phase I clinical trials, IDX-899 reduced HIV-1 RNA and increased CD4+ cell counts in treatment-naïve patients infected with HIV-1. At the time of publication, a phase II clinical trial of IDX-899 was being conducted...
  2. doi request reprint Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C
    Olga M Klibanov
    School of Pharmacy, Wingate University, Wingate, North Carolina 28174, USA
    Pharmacotherapy 32:173-90. 2012
    ..Based on available data, boceprevir is one of the promising novel direct-acting antiviral agents that will likely reshape the treatment of patients with HCV infection...
  3. ncbi request reprint Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection
    Olga M Klibanov
    Wingate University School of Pharmacy, Wingate, NC 28174 0159, USA
    Curr Opin Investig Drugs 10:190-200. 2009
    ..At the time of publication, phase III trials to examine the efficacy and toxicity of elvitegravir were enrolling patients infected with HIV-1...
  4. ncbi request reprint Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection
    Olga M Klibanov
    Wingate University School of Pharmacy, Wingate, NC 28174 0159, USA
    Curr Opin Investig Drugs 10:845-59. 2009
    ..At the time of publication, phase III trials were ongoing or planned to investigate the efficacy and safety of vicriviroc in antiretroviral-naïve and -experienced patients infected with HIV-1...
  5. ncbi request reprint Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection
    Olga M Klibanov
    Wingate University School of Pharmacy, Campus Box 3087, Wingate, NC 28174 0159, USA
    Curr Opin Investig Drugs 11:940-50. 2010
    ..Cenicriviroc is a promising CCR5 inhibitor with potentially important anti-inflammatory effects, and warrants further investigation...
  6. doi request reprint Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C
    Olga M Klibanov
    School of Pharmacy, Wingate University, Wingate, North Carolina, 28174, USA
    Pharmacotherapy 31:951-74. 2011
    ..Telaprevir's most common adverse events included rash, pruritis, and anemia. Based on available data, this new anti-HCV drug will likely be widely used and may revolutionize the treatment of HCV-infected individuals...
  7. doi request reprint Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment
    Jacqueline L Olin
    School of Pharmacy, Wingate University, Wingate, NC, USA
    Ann Pharmacother 46:1671-7. 2012
    ..To review the clinical trials, pharmacologic characteristics, safety, and efficacy of the elvitegravir/cobicistat/emtricitabine/tenofovir single tablet formulation (Stribild)...
  8. ncbi request reprint Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection
    Todd Correll
    Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA
    Pharmacotherapy 28:90-101. 2008
    ..In the future, this class of drugs may become a reasonable treatment option for antiretroviral-naïve patients, but more data are needed in that patient population...